All Information (Except Text) for S.4013 - Pandemic Anti-Monopoly Act116th Congress (2019-2020) |
|Sponsor:||Sen. Warren, Elizabeth [D-MA] (Introduced 06/18/2020)|
|Committees:||Senate - Commerce, Science, and Transportation|
|Latest Action:||Senate - 06/18/2020 Read twice and referred to the Committee on Commerce, Science, and Transportation. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
- Passed Senate
- Passed House
- To President
- Became Law
There is 1 version of this bill. View text
Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries
Actions Overview (1)
|06/18/2020||Introduced in Senate|
06/18/2020 Introduced in Senate
All Actions (1)
|06/18/2020||Read twice and referred to the Committee on Commerce, Science, and Transportation.|
Action By: Senate
06/18/2020 Read twice and referred to the Committee on Commerce, Science, and Transportation.
|Sen. Sanders, Bernard [I-VT]*||06/18/2020|
|Committee / Subcommittee||Date||Activity||Reports|
|Senate Commerce, Science, and Transportation||06/18/2020||Referred to|
Subject — Policy Area:
One Policy Area term, which best describes an entire measure, is assigned to every public bill or resolution.
- Administrative law and regulatory procedures
- Administrative remedies
- Banking and financial institutions regulation
- Cardiovascular and respiratory health
- Civil actions and liability
- Competition and antitrust
- Corporate finance and management
- Drug safety, medical device, and laboratory regulation
- Emergency medical services and trauma care
- Federal Trade Commission (FTC)
- Financial services and investments
- Health technology, devices, supplies
- Infectious and parasitic diseases
- Intellectual property
- Product development and innovation
- Public contracts and procurement
- Research and development
- Strategic materials and reserves
Latest Summary (1)
Introduced in Senate (06/18/2020)
Pandemic Anti-Monopoly Act
This bill places a moratorium on certain mergers and acquisitions during the COVID-19 (i.e., coronavirus disease 2019) pandemic.
Specifically, the bill prohibits certain transactions such as acquisitions (1) by firms with over $100 million in revenue; (2) by financial institutions or equity funds with over $100 million in capitalization; and (3) involving firms with exclusive patents pertaining to COVID-19 pandemic-related production, manufacturing, distribution, or infrastructure. However, a waiver may be granted if the participating firms demonstrate that the transaction will advance critical national security, economic, or public health interests during the emergency.
Further, the bill establishes a legal presumption against a transaction that may pose a risk to the government's ability to respond to the national emergency declared due to COVID-19.